JW (Cayman) Therapeutics Co. Ltd (02126.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 806.63M

MomentumView details →

1D Return

−3.72%

YTD Return

−22.71%

RSI (14)

50.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 806.63M

RSI (14)

50.9

MomentumView details →

1D Return

−3.72%

YTD Return

−22.71%

ProfitabilityView details →

Gross Margin

45.83%

Net Margin

−205.22%

EBITDA Margin

−96.79%

ROE (TTM)

−210.32%

ROA (TTM)

−114.20%

Asset Turnover

0.51x

GrowthView details →

Revenue YoY

+36.20%

EPS YoY

+33.82%

FCF YoY

+90.41%

Revenue CAGR 3Y

+23.78%

EPS CAGR 3Y

+9.09%

EBITDA YoY

+56.07%

EarningsView details →

EPS (Actual)

−HKD 0.14

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.56x

Current Ratio

1.43x

Quick Ratio

1.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

463.57M

Net Income (TTM)

−951.33M

Op. CF (TTM)

—

Next earningsApr 1, 2027 →

Latest newsMore news →

JW Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB111.4 million, up 4.7% year-on-year, and net loss narrowed to RMB50.43 million from RMB267.3 million in the prior-year period.8d ago

Similar companies

CytomX Therapeutics, Inc.CTMX Nuvectis Pharma, Inc.NVCT Pharming Group N.V.PHAR Monopar Therapeutics Inc.MNPR 4D Molecular Therapeutics, Inc.FDMT Aura Biosciences, Inc.AURA Find similar companies →

Latest newsMore news →

JW Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB111.4 million, up 4.7% year-on-year, and net loss narrowed to RMB50.43 million from RMB267.3 million in the prior-year period.8d ago